Ascidian Therapeutics announces the appointment of Murray A. Abramson, MD, MPH, as Chief Development Officer. With extensive experience in clinical development, Dr Abramson will lead the clinical strategy for the company's RNA editing therapeutics.
Who to call at Ascidian Therapeutics, and when
A new leader at Ascidian Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Ascidian Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Ascidian Therapeutics, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Ascidian Therapeutics
Location
Boston, Massachusetts, United States
About
Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ascidian Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BostonBiotechnologyHealth CareMedicalTherapeutics